These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23231385)

  • 1. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.
    Wallace TL; Bertrand D
    Expert Opin Ther Targets; 2013 Feb; 17(2):139-55. PubMed ID: 23231385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.
    Wallace TL; Porter RH
    Biochem Pharmacol; 2011 Oct; 82(8):891-903. PubMed ID: 21741954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease.
    Geerts H
    Expert Opin Investig Drugs; 2012 Jan; 21(1):59-65. PubMed ID: 22047592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.
    Radek RJ; Kohlhaas KL; Rueter LE; Mohler EG
    Curr Pharm Des; 2010 Jan; 16(3):309-22. PubMed ID: 20109141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia.
    Kucinski AJ; Stachowiak MK; Wersinger SR; Lippiello PM; Bencherif M
    Curr Pharm Biotechnol; 2011 Mar; 12(3):437-48. PubMed ID: 21133847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.
    Rao NP; Remington G
    Expert Opin Investig Drugs; 2013 Jul; 22(7):881-94. PubMed ID: 23639138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Nicotine in Schizophrenia.
    Featherstone RE; Siegel SJ
    Int Rev Neurobiol; 2015; 124():23-78. PubMed ID: 26472525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
    Cannon CE; Puri V; Vivian JA; Egbertson MS; Eddins D; Uslaner JM
    Neuropharmacology; 2013 Jan; 64():191-6. PubMed ID: 22659472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
    Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
    Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of nicotinic enhancement of cognitive remediation training in schizophrenia.
    Hahn B; Gold JM; Buchanan RW
    Neuropharmacology; 2013 Jan; 64():185-90. PubMed ID: 22705396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia.
    Timofeeva OA; Levin ED
    Neuroscience; 2011 Nov; 195():21-36. PubMed ID: 21884762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
    Mastropaolo J; Rosse RB; Deutsch SI
    Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia.
    Rowe AR; Mercer L; Casetti V; Sendt KV; Giaroli G; Shergill SS; Tracy DK
    J Psychopharmacol; 2015 Feb; 29(2):197-211. PubMed ID: 25567553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.